First-line gefitinib therapy for elder advanced non-small cell lung cancer patients with epidermal growth factor receptor mutations: Multicenter phase II trial (NEJ 003 study).
Yuji Minegishi, Akihiko Gemma(Nippon Medical School), Masanori Harada(University of Michigan–Ann Arbor), Keigo Kobayashi(Osaka Gakuin University), Shoji Okinaga(Tohoku University), A. Inoue, K. Hagiwara, Makoto Maemondo(Miyagi Prefectural Hospital Organization), T. Nukiwa(Tohoku University), Naoto Morikawa(Tohoku University)
Cited by 20
Related Papers
Gefitinib or Chemotherapy for Non–Small-Cell Lung Cancer with Mutated EGFR
|New England Journal of Medicine|2010|5.6k
Erlotinib plus bevacizumab versus erlotinib alone in patients with EGFR-positive advanced non-squamous non-small-cell lung cancer (NEJ026): interim analysis of an open-label, randomised, multicentre, phase 3 trial
|The Lancet Oncology|2019|642
Durvalumab as third-line or later treatment for advanced non-small-cell lung cancer (ATLANTIC): an open-label, single-arm, phase 2 study
|The Lancet Oncology|2018|579